Admedus Ltd

ABN 35 088 221 078

ASX RELEASE

CHANGE OF REGISTRED OFFICE AND ADDRESS Brisbane, Australia June 8th, 2015

REGISTERED OFFICE:

26 Harris Road

Malaga Western Australia 6090

PO Box 6879

East Perth Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199


E info.au@admedus.com
www.admedus.com
Admedus Limited (ASX:AHZ) advises that, as of June 8, 2015, its registered office and principal place of business has changed.
On 3 January 2015 Admedus announced its acquisition of a manufacturing facility in Western Australia. The Company, as part of its cost management strategy, has moved its registered office into the same facility. This provides for a significant reduction in annual rent with minimal disruption to the business.
The Company's new address and contact details are as follow:

Registered Office & Principle of Business:

26 Harris Road
Malaga, WA 6090

Postal Address:

PO Box 6879
East Perth, WA 6892

Office Contact Details:

Telephone: +61 (0)8 9266 0100
Fax: +61 (0)8 9266 0199
Follow us:
Twitter: @Admedus
Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited
Tel: +61 3 9620 5454

Media: Haley Price

+61 (0) 423 139 163 hprice@admedus.com

Media Europe & Asia

Consilium Strategic Communications
Jessica Hodgson / Ivar Milligan
+44 (0)20 3709 5700 admedus@consilium-comms.com

About Admedus Limited

Admedus (ASX: AHZ) is a diversified, global healthcare company. Our focus is on investing in and developing next generation technologies with world class

partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus has commecialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com

distributed by